Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Loi, Sherene ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Biomarkers; Breast cancer; Immunotherapies; Prognosis; Trastuzumab efficacy; Tumor infiltrating lymphocytes

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TUMOR MARKER;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PROGNOSIS; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DRUG MEGADOSE; GENOMIC INSTABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPH NODE METASTASIS; NONHUMAN; PRIMARY TUMOR; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TH1 CELL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 84886945668     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24720     Document Type: Article

References (10)

1. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992; 28A:859-64; PMID:1524909; http:// dx.doi.org/10.1016/0959-8049(92)90134-N.
2. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al.Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.J Clin Oncol 2013; 31:860-7; PMID:23341518; http://dx.doi.org/10.1200/JCO.2011.41.0902.
3. Simon RM, Paik S, Hayes DF.Use of archived specimens in evaluation of prognostic and predictive biomarkers.J Natl Cancer Inst 2009; 101:1446-52; PMID:19815849; http://dx.doi.org/10.1093/jnci/djp335.
4. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al.Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370.
5. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, et al.Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity.Cancer Res 2013; 73:2493-504; PMID:23418322; http://dx.doi.org/10.1158/0008-5472.CAN-12-4241.
6. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, et al.CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.Cancer Cell 2010; 18:485-98; PMID:21035406; http://dx.doi.org/10.1016/j.ccr.2010.10.002.
7. Clynes RA, Towers TL, Presta LG, Ravetch JV.Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
8. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al.Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.Proc Natl Acad Sci U S A 2011; 108:7142-7; PMID:21482773; http://dx.doi.org/10.1073/pnas.1016569108.
9. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al.Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.J Clin Oncol 2009; 27:5685-92; PMID:19884557; http://dx.doi.org/10.1200/JCO.2008.21.4577.
10. Loi S, Michiels S, Lambrechts D, et al.Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial.Journal of Clinical Oncology 2012; 30:no.15_suppl 507.